What is Jiangxi Fushine Pharmaceutical Co., Ltd.'s (300497.SZ) StockRank?

MoatMap's StockRank for Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) is 41/100, with a Hold signal. This is a composite score combining Quality (42), Value (18), and Momentum (72) factor ranks across MoatMap's 19,000+ stock universe.

Does Jiangxi Fushine Pharmaceutical Co., Ltd. have an economic moat?

Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Jiangxi Fushine Pharmaceutical Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Jiangxi Fushine Pharmaceutical Co., Ltd. in?

Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300497.SZ

HOLDREMOVE

Jiangxi Fushine Pharmaceutical Co., Ltd. · Healthcare · China · $1.2B · Avg Vol: $80M/d

StockRank

P/E (TTM)

1736.0x

ROE

-0.2%

D/E

0.7x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Jiangxi Fushine is an API manufacturer expanding into CDMO services. While it operates in the CDMO space, it lacks the global scale, regulatory validation, and high-value biologics capabilities of tier-1 CDMOs. It operates with low margins and high capital intensity, failing our Terry Smith quality screen.

COMPANY DESCRIPTION

Jiangxi Fushine Pharmaceutical Co., Ltd. manufactures active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, specializing in beta-lactamase inhibitors and carbapenem antibiotics. The company is one of the world's largest producers of sulbactam and tazobactam, serving major global pharmaceutical companies. Its competitive moat is sustained by its large-scale, GMP-compliant manufacturing facilities and high-barrier chemical synthesis processes.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	243M	238M	174M	175M	-10.4%
EPS	-0.04	-0.05	-0.08	-0.01	—
Shares	550M	550M	550M	539M	-2.1%
Debt	210M	240M	237M	244M	5.2%
Equity	396M	367M	322M	323M	-6.6%
Op CF	-18M	-10M	28M	9M	-66.6%
Inv CF	-75M	-52M	-21M	-32M	—
Fin CF	42M	22M	-13M	11M	—

PRICE (1M)-10.0%

SMA 50SMA 200

$2.57

RSI (14)

67.0

52W High

$3.34

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-0.6%44.2

ROE

-0.2%44.7

GP/Assets

6.6%21.0

Op. Margin

22.0%85.2

FCF/Assets

-4.9%36.3

Piotroski

—83.5

Int. Cover

-0.4x38.8

D/E Ratio

0.71x22.4

Current Ratio

1.22x16.0

Value

P/E (TTM)

1736.0x1.4

EV/EBITDA

47.0x7.1

P/FCF

—N/A

P/B

4.2x28.9

P/S

7.1x32.0

Div Yield

—N/A

Momentum

52W High %

77%69.1

RS 6M

8%82.5

SMA 50/200

1.18x87.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

2633%99.1

FUNDAMENTALS

Market Cap

$1.2B

P/E (Forward)

64.3x

Gross Margin

22.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300497.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300497.SZ	Jiangxi Fushine Pharmaceutical Co., Ltd.(you)	$1.2B	41	HOLD
688658.SS	Youcare Pharmaceutical Group Co., Ltd.	$1.2B	39	HOLD
688739.SS	Liaoning Chengda Biotechnology Co.,Ltd.	$1.3B	42	HOLD
603229.SS	Zhejiang Ausun Pharmaceutical Co., Ltd.	$1.2B	43	HOLD
2171.HK	CARsgen Therapeutics Holdings Limited	$1.3B	39	HOLD
600866.SS	Star Lake Bioscience Co., Inc.Zhaoqing Guangdong	$1.2B	46	HOLD
688293.SS	Shanghai OPM Biosciences Co., Ltd.	$898M	42	HOLD
301080.SZ	Acrobiosystems Co.,Ltd.	$1.0B	38	HOLD
688366.SS	Shanghai Haohai Biological Technology Co., Ltd.	$1.1B	48	HOLD
300049.SZ	Inner Mongolia Furui Medical Science Co., Ltd.	$1.7B	40	HOLD

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) — Stock Score Summary

Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) has a MoatMap StockRank of 41/100 based on Quality (42/100), Value (18/100), and Momentum (72/100) factor scores. The current signal is HOLD. Jiangxi Fushine is an API manufacturer expanding into CDMO services. While it operates in the CDMO space, it lacks the global scale, regulatory validation, and high-value biologics capabilities of tier-1 CDMOs. It operates with low margins and high capital intensity, failing our Terry Smith quality screen.

Key Financial Metrics

Price	$2.57
Market Cap	$1.2B
P/E (TTM)	1736.00
P/E (Forward)	64.30
Price/Book	4.16
Return on Equity	-0.2%
Return on Invested Capital	-0.6%
Debt/Equity	71.23
Gross Margin	22.3%
Operating Margin	22.0%
Revenue Growth	53.1%
Free Cash Flow	$-5M

Jiangxi Fushine Pharmaceutical Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Jiangxi Fushine Pharmaceutical Co., Ltd.’s (300497.SZ) StockRank?: MoatMap’s StockRank for Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) is 41/100, with a Hold signal. It is a composite of Quality (42), Value (18), and Momentum (72) factor ranks across MoatMap’s 19,000+ stock universe.
Does Jiangxi Fushine Pharmaceutical Co., Ltd. have an economic moat?: Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Jiangxi Fushine Pharmaceutical Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Jiangxi Fushine Pharmaceutical Co., Ltd. in?: Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).